Evidence mapPaperPMID 40728598Full record

ArticleDigestive diseases and sciences2025

Association Between High FIB-4 Score and the Risk of Malignancy Development and Mortality: A Retrospective Longitudinal Case-Control Study.

Motti Haimi, Fadi Abu Baker, Shlomo Vinker, Rifaat Safadi, Ariel Israel

Abstract read
In one paragraph

Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Motti HaimiHealth Systems Management Department, The Max Stern Yezreel Valey Academic College, Mizra, Israel. mottiha@technion.ac.il.
Fadi Abu BakerThe Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Shlomo VinkerLeumit Research Institute, Leumit Health Services, 23 Sprinzak St, Tel Aviv, Israel.
Rifaat SafadiLiver Institute, Hadassah Medical Organization, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Ariel IsraelLeumit Research Institute, Leumit Health Services, 23 Sprinzak St, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Fibrosis 4 (FIB-4) score, a widely used non-invasive marker for liver fibrosis in chronic liver disease, has recently been linked to systemic inflammation, cardiovascular risk, and mortality. However, its potential role in predicting malignancy risk and long-term outcomes in patients without known chronic liver disease remains unclear.

methodsWe conducted a retrospective case-control study analyzing 43,080 patients from Leumit Health Services in Israel between 2002 and 2023. Of them, 21,540 had high FIB-4 levels > 2.67 and the 21,540 controls had low FIB-4 < 1.5. Patients from both groups were matched 1:1 according to gender, socioeconomic status, and birth year. The study surveyed both the prevalence of malignancies in both groups at baseline and during a 10-year follow-up period.

resultsAt baseline, the high FIB-4 group showed strong associations with existing malignancies, particularly pancreatic cancer (odds ratio [OR] = 27.53), hepatocellular carcinoma (OR = 14), and metastatic stage of any cancer (OR = 17.47). During the 10-year follow-up, while odds ratios decreased, significant risk for developing new malignancies persisted, including hepatocellular carcinoma (OR = 13.63); pancreatic (OR = 5.16), breast (OR = 2.88), and colon cancers (OR = 2.75); and metastatic stage of any cancer (OR = 6.41). The cumulative incidence of solid tumors increased from 15.84% to 22.30% in the high FIB-4 group compared with 4.85% to 9.65% in controls (at baseline and after 10 years, respectively). Additionally, the mortality rate was more than doubled in the high FIB-4 group (20.15% versus 9.72%; OR = 2.34).

conclusionsAn elevated FIB-4 score appears to be associated with both existing malignancies and an increased risk of future cancer development. These associations remain significant independently of traditional cardiovascular risk factors and body mass index (BMI). Our findings suggest that the FIB-4 score may have potential utility as a marker for cancer risk stratification and warrant further investigation in prospective studies.

Indexed as

Liver CirrhosisNeoplasmsAdultAgedCase-Control StudiesFemaleHumansIsraelLongitudinal StudiesMaleMiddle AgedRetrospective StudiesRisk AssessmentRisk FactorsCancer incidenceCancer prevalenceCancer screeningFIB-4 scoreLiver fibrosisMortalityRetrospective study

Identifiers

PMID40728598
PMCPMC12531328

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.